We need to educate both the public and providers on medication-assisted treatment and understand that it is not substituting one drug for another, said Frank James, MD, JD, of American Society of Addiction Medicine.
We need to educate both the public and providers on medication-assisted treatments and understand that it is not substituting one drug for another, said Frank James, MD, JD, of American Society of Addiction Medicine.
Transcript (slightly modified)
How is ASAM working to increase access to medication-assisted treatment?
The first thing is to educate everybody. We know that medication-assisted treatments work. The World Health Organization (WHO), NIDA, SAMHSA, and ASAM have all said that medication-assisted treatment is the standard of care. Just like any other disease process, we need to follow the standard of care. We need to base our treatments on evidence, on research.
So first, educate the public that medication-assisted treatments are not substituting one problem for another. When I was in my clinic, I came across that same bias in the community that if you’re on medicated-assisted treatment, you’re not sober or abstinent; you’re still taking a drug that you can get addicted to. I would say to people like that, “Well, people that were in medication-assisted treatments with me got their lives back, got their kids back, they weren’t going back to jail, and they were staying out of higher levels of care.” People who were on heroin weren’t doing that. They were dying, they’re going back to jail, they’re in an out of hospitals; so, we are not substituting one drug for another. We’re actually giving treatments that are evidence based and actually giving us the outcomes that we want.
Then we have to educate providers. It’s not something that most people are used to prescribing, and there are prescribing practices that we have to make sure people do follow. You don’t have to be an addiction specialist to prescribe medication-assisted treatments, but you have to understand where does that fit in the toolbox of things that we have to treat addiction. It’s not just the medicine that going to cure somebody or get the results they want. It’s collaborating with other providers, community supports, making sure they make their medical appointments. That is one tool that we use for addiction and it’s an important tool.
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More